0

Global Schizophrenia Therapeutics Market 2017-2021

  • Published: Jul 2017
  • Pages: 81
  • SKU: IRTNTR13977
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This market research study identifies AstraZeneca, Eli Lilly, GlaxoSmithKline, and Johnson & Johnson as the leading players in the global schizophrenia therapeutics market. A comprehensive analysis of this market is also presented by drug-class (first-generation antipsychotic drugs, second-generation antipsychotic drugs, and third-generation antipsychotic drugs) and by geography (the Americas, APAC, and EMEA).

Global schizophrenia therapeutics market forecast

Research analysis on the global schizophrenia therapeutics market identifies that the emergence of enhanced next-generation products will have a positive impact on the market’s growth. Chlorpromazine, haloperidol, and fluphenazine are some of the first antipsychotic drugs, which are also known as first-generation or typical antipsychotic drugs. These drugs are not selective in nature and act at the D2 receptor site on the mesolimbic pathway. They are also used to block the D2 receptors present in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. However, with the introduction of second-generation antipsychotic drugs, first-generation drugs were largely out of practice. Clozapine, risperidone, olanzapine, quetiapine, and ziprasidone are some of the second-generation drugs, which are also known as atypical antipsychotic drugs. Researchers are increasingly focusing on the development of newer antipsychotic drugs with lesser side effects and enhanced efficacy. This encourages them to continuously manufacture enhanced antipsychotic drugs. According to the schizophrenia therapeutics industry analysis, this market will grow at a CAGR of close to 2% by 2021.

Get A Free Sample 

The increasing use of long-acting injectable (LAI) antipsychotic drugs is one of the key trends that will propel the growth prospects for the global schizophrenia therapeutics market for the next four years. The LAI antipsychotics drugs can attain higher efficacy in negative and cognitive predominant patients. They improve patient compliance because they are associated with both reduced hospitalization rates and reduced care costs.

Competitive landscape and key vendors

The schizophrenia drugs market is fragmented due to the presence of many leading players. These vendors are increasingly competing against each other based on factors such as emerging indications or applications, major patent expiries, and the rising prevalence of mental disorder in the developed and developing countries. Vendors are losing their market revenue because the market is witnessing the patent expiry of major drugs over the last few years such as ZYPREXA by Eli Lilly and Seroquel by AstraZeneca.

Key vendors in this market are 

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson

Other prominent vendors in the market include Alkermes and Bristol-Myers Squibb.

Segmentation by drug-class and analysis of the schizophrenia therapeutics market

  • First-generation antipsychotic drugs
  • Second-generation antipsychotic drugs
  • Third-generation antipsychotic drugs

The second-generation antipsychotic drugs segment accounted for the majority of market shares during 2016 because these drugs involve fewer side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improve the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This, in turn, will boost the segment’s growth throughout the estimated period.

Segmentation by geography and analysis of the schizophrenia therapeutics market

  • Americas
  • APAC
  • EMEA

Based on the schizophrenia therapeutics market overview, the Americas is experiencing sluggish growth due to patent expiry of major drugs such as Geodon, ZYPREXA, ABILIFY, SEROQUEL, and Prozac. However, vendors in the market are increasingly focusing on the development of DMD for schizophrenia. For instance, the American drug-maker AbbVie is taking efforts to develop schizophrenia treatment drug to treat the cognitive impairment associated with schizophrenia. Similarly, Amgen developed the schizophrenia drug AMG 581 for the treatment of schizophrenia and is conducting Phase I trials for the drug.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

  • What will the schizophrenia therapeutics market size and the growth rate be in 2021?
  • What are the key factors driving the global schizophrenia therapeutics market?
  • What are the key schizophrenia therapeutics market trends impacting the growth of the market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global schizophrenia therapeutics market?
  • What are the market opportunities and threats faced by the vendors in the global schizophrenia therapeutics market?
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
  • What are the key outcomes of the five forces analysis of the global schizophrenia therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

 

Read More Read Less

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Schizophrenia: Disease overview

  • Schizophrenia
  • Medical intervention for treating schizophrenia
  • Non-medical interventions for treating schizophrenia

PART 06: Key clinical trials

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation based on drug-class

  • First-generation antipsychotic drugs
  • Second-generation antipsychotic drugs
  • Third generation antipsychotic drugs

PART 09: Geographical segmentation

  • Market overview based on geography
  • Schizophrenia therapeutics market in Americas
  • Schizophrenia therapeutics market in EMEA
  • Schizophrenia therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Rising public interest toward mental health
  • Increase in use of LAI antipsychotic drugs
  • Availability of drugs with novel mechanism of action (MoA)

PART 13: Vendor landscape

  • Competitive landscape

PART 14: Key vendor analysis

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>